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a b s t r a c t
Studies implicate a potential role for EAF1 in MLL–ELL induced leukemogenesis; however the biological
function of EAF1 in this process remains unknown. In this study, we show that knockdown of zebraﬁsh
eaf1 by morpholinos caused serious defects in both primitive and deﬁnitive hematopoiesis. Using
microarray analysis, we identiﬁed foxo3b as a target gene suppressed by eaf1. Ectopic expression of
foxo3b in embryos mimicked the phenotypes exhibited in eaf1 morphants, except that foxo3b had no
effect on runx1 and c-myb expression while eaf1 morphants did not express these markers in the ventral
wall of dorsal aorta. Subsequent experiments showed that a dominant negative form of Foxo3b (dn-
foxo3b) partially restored primitive hematopoietic defects in eaf1 morphants, suggesting that foxo3b
might serve as a key factor for mediating eaf1 function in primitive hematopoiesis. Furthermore, we
observed that foxo3b inhibited the transcriptional activity of gata1 and spi1 through protein–protein
interaction. Our ﬁndings not only suggest a function of eaf1 on hematopoiesis in vivo, but also reveal a
novel regulatory pathway, eaf1–foxo3b–gata1/spi1, that may shed light on the role of EAF1 in MLL–ELL
induced leukemogenesis.
& 2014 Elsevier Inc. All rights reserved.
Introduction
ELL associated factor 1 (EAF1) was ﬁrst identiﬁed as an associated
factor of ELL (Simone et al., 2001), a fusion partner of MLL in the
t(11;19)(q23;p13.1) chromosomal translocation associated with
acute myeloid leukemia (Thirman et al., 1994). EAF1 interacts with
both the amino-terminus (1–117) (Simone et al., 2003) and the
carboxyl-terminus (401–621) (Simone et al., 2001) of ELL, and
together these proteins form nuclear specks in Cajal bodies (Polak,
2003). An essential event in MLL–ELL-induced leukemogenesis is
the disruption of the association between ELL and EAF1 by MLL–ELL
(Luo et al., 2001). The artiﬁcial fusion protein MLL–EAF1 behaves
similarly to MLL–ELL, immortalizing hematopoietic progenitor cells
in vitro and inducing AML in vivo (Luo et al., 2001). These observa-
tions imply that EAF1 may indirectly or directly contribute to
leukemogenesis.
Using zebraﬁsh, we have demonstrated that zebraﬁsh eaf1 and
eaf2 mediate convergence and extension movements through the
maintenance of wnt11 and wnt5 expression (Liu et al., 2009). In
addition, eaf1 and eaf2 regulate wnt4 expression in a negative
feedback loop (Wan et al., 2010) and negatively regulate canonical
Wnt/β-catenin signaling (Liu et al., 2013). During these studies, we
found that eaf1 knockdown impacted zebraﬁsh blood cell forma-
tion. Given the potential role of EAF1 and its binding partner ELL in
leukemogenesis, we became interested in determining the role of
zebraﬁsh eaf1 in hematopoiesis, which may shed light on mole-
cular mechanisms of MLL–ELL-induced leukemogenesis.
Zebraﬁsh are widely used as a vertebrate model for studying
hematopoiesis due to the ease of manipulating genetic events and
observing the outcomes in these animals (Ellett and Lieschke,
2010; Jing and Zon, 2011). Similar to other vertebrates, zebraﬁsh
hematopoiesis occurs in two successive waves, although the
spatial occurrence sites vary from that of mammals (Detrich
et al., 1995; Galloway and Zon, 2003; Orkin and Zon, 2008). The
ﬁrst wave, termed the primitive wave, occurs at two distinct
locations: the posterior lateral mesoderm (PLM), which migrates
to fuse at the midline at 21 hpf to form intermediate cell mass
(ICM) that predominantly gives rise to primitive erythrocytes
(Detrich et al., 1995); the anterior lateral mesoderm (ALM), which
becomes the rostral blood island (RBI) later, is the major site to
generate primitive macrophages (Herbomel et al., 1999, 2001). The
second wave, termed the deﬁnitive wave, initiates from the ventral
wall of the dorsal aorta (VDA) where hematopoietic stem cells
(HSCS) arose and marked by expression of c-myb (Soza-Ried et al.,
2010; Thompson et al., 1998) and runx1 (Kalev-Zylinska et al.,
2002; Lam et al., 2009), as well as CD41(itga2b) (Bertrand et al.,
2008; Kissa et al., 2008; Lin, 2005; Ma et al., 2011). Elegant lineage
tracing experiments demonstrate that these HSCS subsequently
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migrate to caudal hematopoietic tissue (CHT) (Murayama et al.,
2006) or posterior blood island (PBI) (Jin et al., 2007) before they
home to thymus and kidney. Another population of deﬁnitive
hematopoiesis cells, initiated from PBI at 24 hpf, called erythro-
myeloid progenitors (EMPS) has also been reported (Bertrand et al.,
2007). Compared to HSCS raised from VDA, these cells exhibit
limited differentiated and proliferative potential, lacking the
ability to migrate to deﬁnitive hematopoietic organs and transi-
ently existing to 72 hpf. The orthologs of many transcriptional
factors governing hematopoiesis in mammals function similarly in
zebraﬁsh (Hsia and Zon, 2005; Paik and Zon, 2010), supporting the
notion of a conserved genetic program governing hematopoiesis.
Gata1 and Spi1 (Pu.1) are transcription factors that contribute
to the regulation of hematopoiesis. Disruption of Gata1 in mice
causes severe anemia with arrested erythroblasts maturation by
embryonic day 9.5 (E9.5) and death between E10.5 and E11.5
(Fujiwara et al., 1996). Analysis of zebraﬁsh carrying a gata1
mutation conﬁrms that it modulates erythropoiesis (Belele et al.,
2009; Scott et al., 1994). In mice, depletion of the Ets family
member Spi1 causes death in the late gestational stage and
deﬁciencies in B and T lymphocytes, monocytes and granulocytes
(Scott et al., 1994). Another study showed that, mouse myeloid
development and B lymphocyte differentiation require functional
Spi1 (McKercher et al., 1996). Similarly, in zebraﬁsh, spi1 marks a
site of myeloid development (Lieschke et al., 2002). Thus, Tg(spi1:
EGFP) transgenic zebraﬁsh express GFP in myeloid cells and
immature lymphoid cells (Hsu et al., 2004; Ward et al., 2003).
Knockdown of spi1 in zebraﬁsh causes undetectable expression of
l-plastin and mpo in leukocytes (Bukrinsky et al., 2009; Rhodes
et al., 2005), suggesting its requirement for the generation of
macrophages and granulocytes, while over-expression of spi1 in
cloche mutants rescues myelopoiesis (Rhodes et al., 2005).
In this study, we investigated the role of eaf1 in hematopoiesis
using zebraﬁsh. The results showed that blood cell development
requires eaf1. We further identiﬁed the foxo3b gene as a target of
eaf1 in primitive, but not in deﬁnitive hematopoiesis. Finally, we
demonstrated that Foxo3b represses transcriptional activity of
Gata1 and Spi1 through protein–protein interaction.
Materials and methods
Zebraﬁsh maintenance and cell cultures
Zebraﬁsh (Danio rerio) strain AB, as well as transgenic lines Tg
(ﬂk1::EGFP) (Zhong et al., 2006) (provided by Jianfang Gui,
originally obtained from Shuo Lin), Tg(gata1::EGFP) (provided by
Tingxi Liu) and Tg (spi1::GFP) (provided by Jiuling Du) were raised,
maintained and staged according to standard protocols. HEK293T
cells and COS-7 cells were cultured in DMEM medium or RPMI
1640 medium supplemented with 10% fetal bovine serum.
Morpholinos and their validations
Morpholinos targeting zebraﬁsh eaf1 (NM_001002115) were
designed and synthesized from Gene Tools, LLC (Philomath, Oregon,
USA). Eaf1–MO1: GCGGCGGGTTCGAGCTGCCGTTCAT, Eaf1–MO2:
GAATTCACCAACTTCACCCAAAATG, Eaf1–MO3: GTCTCTCTTGATG-
GACTCACATCTG, Eaf1-mismatch-MO: GTGTGTCTTCATGCACTGA-
CATCTG (5-mismatched nucleotides are underlined), standard
morpholino (STD): CCTCTTACCTCAGTTACAATTTATA.
Eaf–MO1was previously validated (Liu et al., 2009). For Eaf1–MO2
validation, a part of the 50-UTR region of eaf1 was ampliﬁed from a
cDNA pool using primers Eaf1–N1–F and Eaf1–N1–R, and then cloned
intro pAcGFP1-N1 (Clonetech) to generate a reporter vector (WT).
A mutated reporter vector (MT) was cloned using primers Eaf1–N1–
mis-F and Eaf1–N1–R to generate an expression vector with six
nucleotides mutated in the 50-UTR region.
For Eaf1–MO3 validation, three primers were designed: P1
(identical to Eaf1–N1–F), located at exon1; P2, located at the ﬁrst
intron; P3, located at exon2. RT-PCR was employed for validation
after morpholino injection.
All MOs were injected into embryos at the one cell stage. The
dosage of morpholino injected was about 4–16 ng per embryo as
indicated (Eaf1–MO1 or Eaf1–MO2, 8–16 ng/embryo; Eaf1–MO3,
4 ng/embryo). All primer sequences are listed in Supplementary
Table S1.
Plasmid constructions and mRNA synthesis
Zebraﬁsh foxo3b, gata1 and spi1 (pu.1) were ampliﬁed from a
cDNA pool and cloned into pCGN-HAM (provided by William
Tansey) to generate the expression vectors, HA-Foxo3b, HA-
Gata1 and HA-Spi1, respectively. Gata1 and spi1 were also sub-
cloned into pCMV-Myc (Clontech), pM (Clontech) and PM-RFP to
generate Myc-Gata1, Myc-Spi1, pM-Gata1, pM-Spi1, RFP-Gata1 and
RFP-Spi1. The N-terminus of Foxo3b (1–277 amino acids), corre-
sponding the dominant negative form of human FOXO3a (1–304
amino acids) (Charvet et al., 2003) was ampliﬁed from HA-Foxo3b
and subcloned into pCGN-HAM to generate the dominant negative
form of foxo3b (HA-dn-Foxo3b). HA-Foxo3b was subcloned into
pAcGFP1-N1 (Clontech) to generate GFP-Foxo3b.
The full length promoter (2133 to þ1537) of foxo3b was
ampliﬁed from zebraﬁsh total DNA and cloned into pGL3-Basic
(Promega) at KpnI and XhoI sites to generate a foxo3b promoter
luciferase reporter. For generating different deletion foxo3b pro-
moter reporters, the full length promoter reporter was digested by
KpnI and BamHI (1436 to þ1573) or PCR-ampliﬁed (1108 to
þ1537, 746 to þ1537, 625 to þ1537, 385 to þ1537, 310 to
þ1537, 143 to þ1537, 2133(Δ385/310) and 625
(Δ385/310)) for sub-cloning. The 1101 bp of zebraﬁsh runx1
P2 promoter, including the core promoter sequences (Bee et al.,
2009), was PCR-ampliﬁed and sub-cloned into pGL3-Basic. The
(843 to þ253) region of the zebraﬁsh c-myb promoter, corre-
sponding to the human C-MYB promoter region (719 to þ200)
(Palumbo et al., 2008), was PCR-ampliﬁed and cloned into pGL3-
Basic at KpnI and BglII sites. The spi1 promoter was provided by
Tingxi Liu (Hsu et al., 2004)and sub-cloned into pGL3-basic at the
KpnI site. The gata1-reporter containing 6-repeats of Gata1-
binding site (GATAAAGATAGAGATAATGATAGAGATAAAGATAA;
the Gata1 binding sites are underlined) and spi1(pu.1)-reporter
containing 5-repeats of Spil-binding site (GAGGAAGAGGAAGAG-
GAAGAGGAAGAGGA; the Spi1 binding sites are underlined) were
synthesized, annealed and cloned into the pGL2-Promoter (Pro-
mega) at BglII and KpnI sites, with the SV40 minimal promoter
replaced by the TK promoter. Six repeats of the Daf16-binding
elements (DBE) were synthesized (TTGTTTACG TTGTTTACG
TTGTTTACG TTGTTTACG TTGTTTACG TTGTTTACG; DBEs are under-
lined), annealed and cloned into the pGL2-Promoter (Promega) to
generate pGL2-DBE.
For mRNA injection, zebraﬁsh foxo3b and dn-foxo3b (1–227 aa)
were subcloned into the Psp64 poly(A) vector (Promega) and
AmpliCap SP6 High Yield message maker kit (Epicentre) was used
for capped mRNA synthesis. For eaf1 rescue experiments, to avoid
quenching of Eaf1–MO1 by wild-type eaf1 mRNA, a mismatch
mRNA expression vector (which codes wildtype eaf1 protein but
with 5 nucleotide synonymous mutation) was constructed by
PCR using the primer mis-eaf1-F (50-AAGCTTATGAATGGATCTTC-
GAACCCGCCGCTG-30; the ﬁve mismatched nucleotides are
underlined) and Eaf1–N1–R. The dosages of injected mRNA:
foxo3b, 900 pg/embryo; dn-foxo3b, 820 pg/embryo;mis-eaf1-mRNA,
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600 pg/embryo. All constructs were conﬁrmed by sequencing. The
primers are listed in Supplementary Table S1.
Whole mount in situ hybridization and O-dianisidine staining
Whole mount in situ hybridization (WISH) was performed as
described previously (Liu et al., 2009) except for runx1 staining,
which was performed according to the protocol described by
(Kalev-Zylinska et al. (2002). Probes for alas2, hbae1, hbae3, hbbe1,
rag-1, rag-2, foxo3b, foxo1a, foxo3a, foxn1, scl, lmo2, gata1, spi1,mpo,
l-plastin, c-myb and runx1 were ampliﬁed from the cDNA pool
using primers listed in Supplementary Table S1 and cloned into
pTA2 (Toyobo); Probes for ﬂk-1 and ﬂt4 were provided by Jianfang
Gui (Institute of Hydrobiology, Chinese Academy of Sciences);
Probes for gata2 was provided by Tingxi Liu (Institute of Health
Sciences, Chinese Academy of Sciences); Probe for ephrinB2a was
provided by Zhan Yin (Institute of Hydrobiology, Chinese Academy
of Sciences). O-dianisidine staining for hemoglobin was performed
as previously described (Detrich et al., 1995)
Validation for injected mRNA
To conﬁrm that the injected mRNAs were expressed in
embryos, we fused a Myc-tag to the N-terminus of eaf1, foxo3b
and dn-foxo3b and subcloned the constructs into the Psp64 poly
(A) vector (Promega). AmpliCap SP6 High Yield message maker kit
(Epicentre) was used for capped mRNA synthesis. At different
time points, the embryos injected with mRNAs were harvested
and Western blot conducted using anti-Myc antibody (9E10,
Santa Cruz).
Cell sorting
The embryos were dissociated and cell suspensions were
prepared as previously described (Chan and Cheng, 2003; Liu
et al., 2007) with some modiﬁcation. Gata1eGFPþ /(48 hpf)
embryos (200 embryos/sample) were obtained from crossing
mature gata1eGFPþ /þ ﬁsh with wild-type AB line ﬁsh. spi1eGFPþ /
(24 hpf) and sibling embryos were obtained from crossing adult
spi1eGFPþ / ﬁsh with wild-type AB line ﬁsh, GFP positive embryos
(150 embryos/sample) were collected under ﬂuorescent micro-
scope. Followed by twice washing with PBS, embryos were
dechorionated with Pronase E (Sigma) and washed three times
with cold PBS to remove residual Pronase. The embryos were
transferred into 3.5 mm culture dish and disaggregated in 2.5 ml
trypsin solution (2.5 mg/ml trypsin in 0.9 PBS with 5% FBS) at
28 1C for 20 min with several gentle mixtures using tips every
6 min. Cell suspensions were ﬁltered through 70 μm nylon mesh
(BD) and centrifuged at 1000 rpm for 5 min. Cell pellets were
resuspended in 1 ml Cell Dissociation Solution Non-enzymatic 1
Hanks (Sigma) and incubated at 37 1C for 15 min with gentle
shaking for three times. 1 ml L15 Leibovitz medium (Hyclone)
containing 20% FBS (Hyclone) were added to stop dissociation and
centrifuged at 1000 rpm for 5 min. Cell pellets were resuspended
in 2 ml PBS (Hyclone) and ﬁltered through 40 μm nylon mesh
(BD). Cell suspensions were centrifuged at 1000 rpm for 5 min and
resuspended in 500 μl to 1 ml cold PI staining buffer (1 μg/ml PI in
PBS). Followed by staining at room temperature for 5 min, the cells
were gently mixed and put on ice immediately for green
ﬂuorescence-activated cell sorting (FACS) using a FACSAria III ﬂow
cytometer (BD).
Total RNA was extracted from sorted cells by RNeasy Micro Kit
(Qiagen) following the protocol provided by the manufacture. cDNA
synthesis was performed by M-MLV ﬁrst strand kit (Invitrogen)
following the protocol supplied by the manufacture.
RNA isolation and semi-quantitative real-time PCR
Total RNA was extracted from about 50 embryos using RNA
Isolation Plus Reagent (Takara). Double-stranded cDNA was
synthesized using Revert Aid™ ﬁrst strand cDNA synthesis kit
(Fermentas). Semi-quantitative RT-PCR was performed as
described (Wan et al., 2011). The primers for c-myb (Wan et al.,
2011), runx1 (Wan et al., 2011), mpo (Bertrand et al., 2008) were
used as described previously. The primers for hbbe1, hbae3,
l-plastin, alas2, myoD, foxo3b and 18 s RNA are listed in
Supplementary Table S1. The data are reported as mean 7S.E.M.
(the standard error of the mean) of three independent experi-
ments performed in triplicate. The statistic analysis was performed
using GraphPad Prism 5.0 (non-paired t tests).
Luciferase reporter assays and transcriptional activity assays
Luciferase reporter assays were performed as described pre-
viously (Xiao et al., 2006) For embryos, the plasmids were injected
into the embryos at the one-cell stage. About 20 embryos were
harvested at 9–10 hpf and homogenized in Passive Lysis Buffer
(Promega). Each experiment was conducted in triplicate and
repeated at least three times. Zebraﬁsh gata1 and spi1 were cloned
into PM vector (Clontech) to fuse with GAL4–DNA binding domain
(PM-Gata1, PM-Spi1). pFR luciferase reporter (Strategene) contain-
ing ﬁve GAL4 binding sites was used as a reporter. pTK-Renilla
luciferase vector was used as an internal control. Data were
presented as means7S.E.M of three independent experiments
performed in triplicate.
Whole-embryo chromatin immunoprecipitation, Western blot and
co-immunoprecipitation
Whole-embryo chromatin immunoprecipitation (E-ChIP) was
performed as described previously (Wardle et al., 2006), with
minor modiﬁcations. Brieﬂy, 100 embryos injected with HA-Eaf1,
HA-MyoD or HA-empty vectors (62.5 pg/embryo) were harvested
at 10 hpf (hours post fertilization) and ﬁxed in 1.85% Formalin.
Chromatin was sonicated into 300–750 bp fragments and 40 μl
protein A/G agarose beads (Santa Cruz) per sample were added to
pre-clear lysates at 4 1C for 1 h. The supernatant was then
incubated with 2 mg of mouse anti-HA antibody (Covance) or
mouse IgG (control) (Santa Cruz) on a rotor overnight at 4 1C.
The primers for amplifying the promoter region of foxo3b are listed
in Supplementary Table S1. β-actin served as a control(Hart et al.,
2007). Western blots and co-immunoprecipitation were per-
formed as described previously (Xie et al., 2011). Anti-Myc
(9E10) monoclonal antibody was purchased from Santa Cruz. HA
monoclonal antibody-conjugated agarose beads were purchased
from Sigma.
Microscopy and imaging
Embryos were observed with a Leica M205FA dissection
microscopy. The pictures were taken with Nikon DS-Ri1 digital
camera.
Results
Loss of zebraﬁsh eaf1 caused defects in both primitive and deﬁnitive
hematopoiesis
We previously found that zebraﬁsh embryos display ubiquitous
eaf1 expression during early developmental stages and blocking
this expression via Eaf1–MO1, a morpholino that speciﬁcally
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targets the ATG start site of eaf1, (Liu et al., 2009) reduced blood
cells in circulation (Supplementary Video S1). These phenomena
led us to hypothesize that zebraﬁsh eaf1 may have an important
function on hematopoiesis.
Supplementary material related to this article can be found
online at http://dx.doi.org/10.1016/j.ydbio.2014.01.005.
To ensure the speciﬁcity of morpholino-mediated knockdown of
eaf1, we used three morpholinos, Eaf1–MO1, Eaf1–MO2 (targeting the
50-UTR region of eaf1), and Eaf1–MO3 (targeting the linkage region
between exon 1 and intron 1 of eaf1 to block splicing) to knockdown
of eaf1 in zebraﬁsh embryos. In addition, a standard morpholino
(STD-MO) and Eaf1-mismatch-MO (a morpholino harbors 5 mis-
matched nucleotides corresponding to Eaf1–MO3) were used as
controls. The speciﬁcity and efﬁciency of Eaf1–MO2 and Eaf1–MO3
mediated eaf1 knockdown, as well as no effect of Eaf1-mismatch-MO
on eaf1 splicing was veriﬁed (Supplementary Fig. S1).
We examined hemoglobin levels by O-dianisidine staining to
monitor erythropoiesis in embryos injected with morpholinos.
Compared to the control embryos (STD-MO) (Supplementary Fig.
S2A (a, d and g); Fig. 1A (a)), the embryos injected with Eaf1–MO1
(8–16 ng/embryo) (Supplementary Fig. S2A (b, e, and h)), Eaf1–
MO2 (8–16 ng/embryo) (Supplementary Fig. S2A (c, f and i)) or
Eaf1–MO3 (4 ng/embryo) (Fig. 1A (b)) displayed similar defects in
erythropoiesis. Even at 6.5 dpf (days post fertilization), eaf1
morphants had signiﬁcantly less hemoglobin staining as compared
with controls (STD-MO) (Supplementary Fig. S2B). In addition, the
embryos injected with Eaf1-mismatch-MO exhibited normal ery-
thropoiesis compared to wildtype controls (Supplementary Fig. S2C).
Fig. 1. Knockdown of zebraﬁsh eaf1 by the splicing–blocking morpholino (Eaf1–MO3) blocks hematopoiesis, but does not affect expression of early hematopoietic
marker genes, except for spi1. (A) Knockdown of eaf1 reduced O-dianisidine staining of hemoglobin obviously at 36 hpf (b versus a). (B) The reduction of hemoglobin
(b, stained by O-dianisidine) resulted from knockdown of eaf1 was partially rescued by co-injecting mismatch mRNA of eaf1 at 4.5 dpf (c). (C) Depletion of eaf1 did not alter
the expression of scl (a and b), lmo2 (c and d) and gata2 (e and f) at 10 s in the posterior lateral mesoderm. (D) At 10s and 22 hpf, expression of gata1 was not affected by
depletion of eaf1 in the posterior lateral mesoderm (a and b) and ICM (c and d). (E) At the 10s, depletion of eaf1 enhanced expression of spi1 in the anterior lateral mesoderm
(a and b). (F) At 22 hpf, expression of spi1 was reduced by depletion of eaf1 (a–d). (G) At 22 hpf, the number of GFP-positive cells in spil::GFP transgenic zebraﬁsh was
reduced by depletion of eaf1 (a–d). hpf, hours post fertilization; dpf, days post fertilization; s, somite; ICM, intermediate cell mass. Eaf1–MO3, 4 ng/embryo; eaf1-mismatch
mRNA, 600 pg/embryo.
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These observations suggest that eaf1 depletion might disrupt both
primitive and deﬁnitive erythropoiesis.
To determine whether the hematopoietic defects exhibited in
eaf1 morphants were resulted from a non-speciﬁc morpholino
effect, we performed rescue experiments using a mismatch eaf1
mRNA (eaf1 mismatch-mRNA) (harboring 5 synonymously
mutated nucleotides to avoid quenching by Eaf1–MO1). After co-
injection of Eaf1–MO1 together with eaf1 mismatch-mRNA, the
embryos were not well rescued in hemoglobin expression at
52 hpf as compared with the embryos injected with Eaf1–MO1
plus GFP mRNA (Supplementary Fig. S3A). But, co-injection of
Eaf1–MO3 together with eaf1 mismatch-mRNA could indeed
rescue hemoglobin expression in the embryos at 4.5 dpf (Fig. 1B).
We noticed that Eaf1–MO3 caused defects in erythropoiesis at a
relative lower dosage (4 ng/embryo for Eaf1–MO3 versus 8–16 ng/
embryo for Eaf1–MO1 or Eaf1–MO2). In addition, the lower dosage
of Eaf1–MO3 appeared to generate less morphological defects
other than hematopoiesis (data not shown). In order to investigate
the function of eaf1 in hematopoiesis speciﬁcally, we chose Eaf1–
MO3 as a main tool to knock down of eaf1 for further assays.
We next examined the expression of a variety of hematopoietic
markers in Eaf1–MO3 morphants using whole mount in situ
hybridization (WISH). There were no obvious alterations in
expression of the early hematopoietic progenitor markers scl and
lmo2, as well as gata2 in the posterior lateral mesoderm (PLM) at
the 10s (Fig. 1C). We saw similar results for gata1 expression
Fig. 2. Expression of hematopoietic markers are reduced by eaf1 depletion. (A) signiﬁcant reductions of erythrocytic markers hbae1 (a and b), hbae3 (c and d) and hbbe1
(e and f) were detected in eaf1-knocked down embryos at 48 hpf; expression of alas2 was also decreased in the ICM of eaf1-knock down embryos at 30 hpf (g and h). (B) The
myelomonocytic marker l-plastin was reduced in eaf1-knock down embryos at 22 hpf and 48 hpf. (C) The granulocyte-speciﬁc marker mpo was reduced in eaf1-knocked
down embryos at 24 hpf and 48 hpf. (D) Expression of deﬁnitive hematopoiesis marker runx1 was sharply diminished in the ventral wall of dorsal aorta in eaf1morphants at
31 hpf, 36 hpf and 48 hpf (a–h); semi-quantitative RT-PCR assays conﬁrmed that expression of runx1 (i) was reduced in eaf1 morphants, but was recovered by the
co-injection of eaf1 mismatch mRNA. (E) Expression of deﬁnitive hematopoiesis marker c-myb was sharply diminished in the ventral wall of dorsal aorta in eaf1 morphants
at 31 hpf, 36 hpf and 48 hpf (a–h); semi-quantitative RT-PCR assays conﬁrmed that expression of c-myb (i) was reduced in eaf1 morphants, but was recovered by the
injection of eaf1 mismatch mRNA. (F) The lymphoid marker rag1 was abolished in eaf1 morphants at 3.5 dpf (a and b) and 4.5 dpf (c and d). (G) The co-injection of eaf1
mismatch mRNA rescued rag1 expression at 4.5 dpf (a–c). (H) The lymphoid marker rag2 was abolished in eaf1 morphants at 3.5 dpf (a and b) and 4.5 dpf (c and d). (I) The
co-injection of eaf1 mismatch mRNA rescued rag2 expression at 4.5 dpf (a–c). Eaf1–MO3, 4 ng/embryo.
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(Fig. 1D (a–d)), a principal early erythroid marker. However, the
expression of early myeloid cell marker spi1 in the anterior lateral
mesoderm (ALM) was enhanced at 10s (Fig. 1E (a and b)), but
reduced at 22 hpf (Fig. 1F (a–d)) in eaf1 morphants. The reduction
of spi1 in Eaf1–MO3 morphants at 22 hpf was further conﬁrmed
by Tg(spi1::GFP) transgenic zebraﬁsh embryos. In Eaf1–MO3
morphants, less GFP (driven by spi1 promoter) positive cells were
detected (Fig. 1G (a–d)).
In agreement with the results obtained by O-dianisidine stain-
ing, eaf1 morphants expressed reduced levels of the hemoglobin
markers hbae1, hbae3, hbbe1 at 48 hpf and alas2 at 30 hpf (Fig. 2A).
Furthermore, eaf1 knockdown also disrupted primitive myelopoi-
esis, as indicated by reduced staining of myelomonocytic marker l-
plastin at 22 hpf and 48 hpf (Fig. 2B (a–d)), and granulocytic-speciﬁc
marker mpo at 24 hpf and 48 hpf (Fig. 2C (a–d)). Similar to that of
Eaf1–MO3 injections, the embryos injected with Eaf1–MO1 also
caused decreasing expression of erythrocytic marker, hbbe1 and
myeloid markers l-plastin and mpo. Co-injection of eaf1-mismatch
mRNA could partially restore these gene expressions to the levels
seen in wildtype embryos (control) (Supplementary Fig. S3B–D).
Western blots using anti-Myc antibody conﬁrmed expression of
Myc tagged mismatched eaf1 (Supplementary Fig. S3E).
Moreover, the hematopoietic stem cell (HSC) markers runx1
and c-myb were obviously reduced in the ventral wall of the
dorsal aorta in eaf1-depleted embryos at 31 hpf, 36 hpf and 48 hpf
(Fig. 2D (a–h); E (a–h)), which we conﬁrmed by semi-quantitative
RT-PCR assays (Fig. 2D (i); E (i)). Co-injection of eaf1-mismatch
mRNA could restore expression of runx1 and c-myb in Eaf1
morphants as revealed by semi-quantitative RT-PCR assays
(Fig. 2D (i); E (i)).
In addition, eaf1 morphants lacked expression of T lymphocyte
markers rag-1 and rag-2 at the bilateral thymus at 3.5 dpf and
4.5 dpf, and co-injection of eaf1-mismatch mRNA could restore
their expression respectively at 4.5 dpf (Fig. 2F–I). However, the
thymus developed normally as indicated by the thymic epithelium
marker foxn1 staining (Supplementary Fig. S4), suggesting the
failure of lymphoid cell development rather than of thymus
development.
By contrast, the embryos injected with Eaf1-mismatch-MO
showed no obvious alternation in expression of hbbe1, hbae3,
mpo and l-plastin (Supplementary Fig. S5A and B).
Even though the major evidence shown above indicated that the
number of circulating red blood cells was reduced, it was still unclear
whether reduced gene expression exhibited in eaf1morphants is due
to a reduction of cell number, or a reduced gene expression in every
cell, or both. To further address this concern, we took advantage of Tg
(gata1::GFP) and Tg(spi1::GFP) transgenic zebraﬁsh. After sorting
nearly the same number of Gata1-GFP positive cells from embryos
by a FACS machine, we examined expression of hbbe1 and hbae3 by
semi-quantitative RT-PCR assays and found that their expression was
indeed reduced by depletion of eaf1 in embryos (Supplementary Fig.
S6A); similarly,mpo expression was also reduced in Spi1-GFP positive
cells of Eaf1–MO3 morphants (Supplementary Fig. S6B). These results
suggest that knockdown of eaf1 not only cause a reduction of blood
cell number, but also can cause a reduced gene expression in
every cell.
The defects in blood vessel formation can also cause blood ﬂow
abnormalities and reduction of blood cell numbers. To determine
whether depletion of eaf1 affected blood vessel formation, we
injected Eaf1–MO3 into embryos of the transgenic zebraﬁsh line
Tg(ﬂk1::GFP), which expresses GFP in endothelial cells. No obvious
defects were observed in the overall vasculature at 32 hpf and
55 hpf (Supplementary Fig. S7A (c–f)). WISH assays for ﬂk-1 and
ﬂt4 at 30 hpf further conﬁrmed that the axial vasculature, inter-
segmental blood vessels and caudal vein appeared normal in eaf1
morphants (Supplementary Fig. S7A (a and b); B (a and b).
Moreover, the staining for arterial marker ephrinB2a at 30 hpf also
showed that depletion of eaf1 did not affect the dorsal aorta
(Supplementary Fig. S7C). These results indicate that knockdown
of eaf1 did not cause obvious defects in vasculogenesis, further
reinforcing a speciﬁc role for eaf1 in hematopoiesis.
Taken together, these results suggest that eaf1 is required for
both primitive hematopoiesis and deﬁnitive hematopoiesis.
Zebraﬁsh eaf1 directly suppressed foxo3b expression
To gain insight into the mechanism by which eaf1 regu-
lates hematopoiesis, we investigated expression proﬁling in eaf1
morphants (3 somite stage) using a zebraﬁsh oligonucleotide
microarray that represents about 44,000 genes (Agilent). In three
parallel repeated arrays, we found that only one known gene
(hibadh) was down-regulated (three-fold change was used as cut-
off), but nine known genes (foxo3b, bax, gnmt, upb1, rlbp1, vrk2,
crygn1, gadd45al and addoc) were up-regulated (three-fold change
was used as cut-off) (data not shown). Among the 9 up-regulated
genes, foxo3b (also designated as foxo5) had the highest-fold
change (4.964, 5.343 and 4.815, respectively). Zebraﬁsh foxo3b
has a close relationship with its mammalian orthologue FOXO3a,
as well as similar gene composition (Fig. 3A and B). Studies have
shown that Foxo3a contributes to regulating hematopoiesis
(Bakker, 2004; Miyamoto et al., 2007; Sykes et al., 2011). Thus,
we speculated that foxo3b might serve as a factor for mediating
eaf10s function in hematopoiesis.
As reported, the expression of foxo3b in early embryogenesis of
zebraﬁsh was ubiquitous (data not shown) (Xie et al., 2011).
Employing WISH and semi-quantitative RT-PCR, we showed that
injection of eaf1 morpholinos dramatically up-regulated foxo3b
(Fig. 3C; Supplementary Fig. S8A) whereas the control (STD-MO),
Eaf1-mismatch-MO, did not (Supplementary Fig. S8D). Semi-
quantitative RT-PCR assays not only conﬁrmed up-regulation of
foxo3b by Eaf1–MO3 injection, but also showed that co-injection of
eaf1-mismatch mRNA could partially neutralize the enhancement
effect of Eaf1–MO3 on foxo3b expression, particularly for the
embryos at 30 hpf (Fig. 3C (g). However, the other two homologs
of foxo3b in zebraﬁsh, foxo3a and foxo1a, were not altered in eaf1
morphants (Supplementary Fig. S8B and C). In addition, the Spi1-
GFP cells sorted from Eaf1–MO3 morphants also exhibited higher
foxo3b expression compared to the embryos without Eaf1–MO3
injection as revealed by Semi-quantitative RT-PCR assays
(Supplementary Fig. S8E). These observations suggest that eaf1
suppresses foxo3b expression speciﬁcally.
We next determined whether eaf1 directly inhibited expression
of the foxo3b gene using promoter assays. We constructed a series
of foxo3b promoter deletion reporters (Fig. 3D) along with a vector
expressing HA-tagged eaf1. We transfected HEK293T cells with
these constructs and used Western blot analysis to conﬁrm the
expression of HA-tagged eaf1 (Fig. 3E). The overexpression of eaf1
in HEK293T cells signiﬁcantly inhibited activity of 5 of the foxo3b
promoter reporters (2133 to þ1537, 1436 to þ1537, 1108 to
þ1537, 746 to þ1537, 625 to þ1537; po0.05), but did not
inhibit activity of two others (310 to þ1537 and 143 to
þ1537) (Fig. 3F). These observations imply that the response
element for eaf1 suppression might localize between the 625
and 310 region of the foxo3b promoter. To conﬁrm this possibi-
lity, we repeated the promoter assays in embryos and found that
ectopic expression of eaf1 in embryos dramatically inhibited
activity of the 625 to þ1537 promoter, but not of the 310 to
þ1537 and 143 to þ1537 promoters (Fig. 3G). Consistently,
knockdown of eaf1 in embryos enhanced activity of the 625 to
þ1537 promoter, but not the activity of the 310 to þ1537
promoter (Fig. 3H). To further map the response element of eaf1 on
foxo3b promoter, we made an additional promoter reporter 385
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to þ1573. Ectopic expression of eaf1 in embryos could still inhibit
the activity of the 385 to þ1573 promoter (Fig. 3I). Then, we
deleted 385 to 310 region from the full length promoter
reporter (2133 to þ1573) and the 625 to þ1573 promoter
reporter. As shown in Fig. 3J, ectopic expression of eaf1 in embryos
could not suppress these two truncated promoter reporter0s
Fig. 3. Eaf1 directly suppresses expression of zebraﬁsh foxo3b, an orthologue of human FOXO3a. (A) Alignment of zebraﬁsh foxo3b and human FOXO3a amino acid sequences.
Identical amino acids are indicated by dots; the phosphorylation sites by human AKT and putative phosphorylation sites by zebraﬁsh akt are underlined and labeled by red
color; the dominant negative form of either human FOXO3a or zebraﬁsh Foxo3b is marked by blue arrows and numbered. (B) Phylogenetic tree of FOXO proteins was
constructed by Neighbor Joining method. The bootstrap values are marked at each branch. Foxo3a mouse (NM_019740), Foxo3a Rat (NM_001106395), Foxo3a human
(NM_001455), foxo3b zebraﬁsh (NM_131085), Foxo3a zebraﬁsh (NM_001009988), Foxo4 human (NM_5938), Foxo4 mouse (NM_018789), Foxo1 human (NM_002015), Foxo1
mouse (NM_019739), foxo1a zebraﬁsh (NM_001077257), foxo1b zebraﬁsh (NM_001082857). (C) Expression of foxo3b was increased dramatically by Eaf1–MO3-mediated
eaf1 knockdown (b versus a; e versus d), but was decreased when mismatch mRNA of eaf1 was co-injected (c versus b; f versus e) at 10s and 30 hpf; semi-quantitative RT-
PCR conﬁrmed enhancement of foxo3b expression in eaf1 depleted-embryos, and reduction of foxo3b expression when mismatch mRNA of eaf1 was co-injected at 10s and
30 hpf (g). (D) Schematic depiction of different deletion constructs of foxo3b promoter luciferase reporter. (E) Expression of HA-tagged Eaf1 in 293 T cells was conﬁrmed by
Western blot using anti-HA monoclonal antibody. (F) Luciferase reporter assays for different deletion constructs of the foxo3b promoter in the presence or absence of HA-eaf1
in 293 T cells. The eaf1 response region on the foxo3b promoter was mapped to the 625 to 310 region (“þ1” is designated as the transcription initial site; the translation
starting site (ATG code) is located in “þ1564”). (G) The suppressive role of eaf1 on foxo3b promoter constructs was re-evaluated in embryos. Ectopic expression of eaf1 in
embryos dramatically inhibited transactivation function of the foxo3b promoter construct 625 to þ1573, but not the promoter constructs 310 to þ1573 or 143 to
þ1573. (H) The suppressive role of eaf1 on foxo3b promoter construct 625 to þ1573 was further evaluated by eaf1 knockdown assays in embryos. Compared to standard
morpholino (STD-MO) injection (control), the activity of foxo3b promoter 625 to þ1537 was up-regulated dramatically by eaf1–MO1 injection, but the activity of the
foxo3b promoter 310 to þ1537 was not. (I) Further mapping for eaf1 response region in foxo3b promoter narrowed down to 385 to 310. (J) When the region of 385 to
310 in foxo3b promoter was deleted in both 2133 to þ1573 promoter reporter and 625 to þ1573 promoter reporter, ectopic expression of eaf1 could not suppress
these two reporters0 activity. The dosage of promoter constructs was 1.25 pg/embryo; HA-empty vector and HA-eaf1, 62.5 pg/embryo; pRL-SV40 (internal control), 25.0 pg/
embryo. (K) The expressions of HA-Eaf1, HA-Gata1, HA-Spi1 and HA-Foxo3b in embryos after plasmid injections were conﬁrmed by Western blot using anti-HA monoclonal
antibody. (L) Whole-embryo chromatin immunoprecipitation (E-ChIP) assays showed that Eaf1 bound to the foxo3b promoter at the region between 625 and 291. The
foxo3b promoter fragment covering 625 to 291 was immunoprecipitated by anti-HA antibody (c, the fourth lane from left to right), but not by mouse IgG (control) (c, the
third lane from left to right). Zebraﬁsh β-actin promoter and the region of 2072 to 1770 in foxo3b promoter were used as negative controls (a and b). 25% of input DNA
(total DNA) served as a positive control (a–c).
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activity. Expression of the HA-Eaf1 protein in embryos was
conﬁrmed by Western blot assays (Fig. 3K).
To determine whether eaf1 can directly bind to the foxo3b
promoter region 625 to 310, we employed whole-embryo
chromatin immunoprecipitation assays (E-ChIP). Embryos were
injected with vector expressing HA-tagged eaf1 and were lysed
after 10 h. As shown in Fig. 3L, the foxo3b promoter region 625
to 291 could be immunoprecipitated by anti-HA antibody, but
not by mouse IgG control (Fig. 3L (c)). However, a region (2072
to 1770) far from the region 625 to 310 could not be
immunoprecipitated by anti-HA antibody (Fig. 3L (b)) as well as
the negative control β-actin (Fig. 3L (a)). To further ensure the
speciﬁcity of Eaf1 binding to foxo3b promoter, we used HA-myoD
as a parallel control to perform E-ChIP assays. As showed in
Supplementary Fig. S9, HA-eaf1 could be easily detected binding
to foxo3b promoter region 625 to 291, but HA-myoD could not
(Supplementary Fig. S9). These results suggest that eaf1 directly
suppresses foxo3b expression by directly binding to its promoter.
Ectopic expression of foxo3b in embryos mimicked the effects of eaf1
knockdown to disrupt primitive hematopoiesis
Given that the mammalian orthologue, Foxo3a, plays a role in
hematopoiesis, we initially examined whether foxo3b has a similar
sub-cellular localization. As shown in Supplementary Fig. S10, we
observed that GFP-tagged foxo3b primarily resided in the cyto-
plasm of HEK293T cells, but addition of LY294002 (20 μM), a PI3 K
inhibitor, resulted in its translocation into the nucleus, similar to
Fig. 4. Ectopic expression of foxo3b impairs primitive hematopoiesis mimicking that of eaf1 knockdown. (A) Erythropoiesis was disrupted by injection of foxo3b mRNA.
At 52 hpf, O-dianisidine staining showed lower hemoglobin levels at the ventral yolk in embryos injected with foxo3b mRNA (b) as compared with control embryos injected
with the same dosage of GFP mRNA (a). At 48 hpf, expression of hbae3 (d) and hbbe1 (f) was reduced in embryos injected with foxo3b mRNA as compared with control
embryos injected with GFP mRNA (c and e, respectively); at 24 hpf, expression of alas in the posterior blood island was reduced in embryos injected with foxo3bmRNA (h) as
compared with embryos injected with GFP mRNA (g). (B) Semi-quantitative RT-PCR conﬁrmed that the reduction of expression of alas2 in embryos injected with foxo3b
mRNA as compared with embryos injected with GFP mRNA, but expression of mesoderm markermyoD was not altered (a); the expression of injected foxo3bmRNA in 26 hpf
embryos was conﬁrmed by Western blot using anti-Myc antibody (b). (C) Expression of myeloid markers l-plastin (b) and mpo (d) was reduced in embryos injected with
foxo3b mRNA as compared with embryos injected with GFP mRNA (a and c) at 48 hpf. (D) Deﬁnitive hematopoiesis was not affected by ectopic expression of foxo3b. No
obvious alternations of deﬁnitive hematopoiesis markers runx1 (a and b) and c-myb (c and d) were detected in embryos with ectopic expression of foxo3b. (E) The lymphoid
markers rag1 and rag2 were not altered after ectopic expression of foxo3b at 4.5 dpf (b versus a; d versus c). foxo3b mRNA, 900 pg/embryo.
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what has been reported for FOXO3a (Brunet et al., 1999). AKT-
mediated phosphorylation of FOXO3a at three sites (T32, S253 and
S315), blocks translocation to the nucleus. We mutated the
corresponding sites on foxo3b (T30, S223 and S289) to alanine
(GFP-tagged foxo3b-TM) and observed that the protein remained
predominately in the nucleus (Supplementary Fig. 10C), under-
scoring the similarity between the two proteins.
To explore a possible role of foxo3b in hematopoiesis, we
injected synthesized capped foxo3b mRNA into embryos at the
one-cell stage. Compared to embryos injected with a GFP mRNA
control, about one third of the embryos with foxo3bmRNA (n¼17/
54) showed a considerable decrease in hemoglobin levels in the
major heart vessels at 52 hpf (Fig. 4A (a and b)). WISH assays also
showed a reduction, at 48hpf, in the expression of the hemoglobin
markers, hbae3 (Fig. 4A (c and d)) and hbbe1 (Fig. 4A (e and f)) in
embryos injected with foxo3b mRNA. In addition, foxo3b mRNA
corresponded with reduced expression of the erythropoietic
marker, alas2 (Fig. 4g and h). We conﬁrmed the decrease in
expression of alas2 by semi-quantitative RT-PCR, but expression
of myoD was not altered (Fig. 4B (a)). The expression of injected
foxo3b mRNA was conﬁrmed by Western blot assays using anti-
Myc antibody (Fig. 4B (b)). Like eaf1 depletion (Fig. 2B and C),
ectopic expression of foxo3b also diminished levels of l-plastin and
mpo (Fig. 4C). Together, these results show that ectopic expression
of foxo3b in embryos produced phenotypes similar to those
exhibited by eaf1 morphants with regard to disruption of erythro-
poiesis and myelopoiesis.
However, foxo3b mRNA did not fully recapitulate the pheno-
types produced by eaf1 knockdown. For example, while both eaf1
depletion and foxo3b mRNA injection did not alter scl, lmo2, gata1
expression at 10s (Supplementary Fig. S11A–C), foxo3b did reduce
expression of spi1 at 10s, which is contrary to spi1 expression in
eaf1 morphants (Supplementary Fig. S11D). Moreover, for the
deﬁnitive hematopoietic markers, runx1 and c-myb, unlike the
embryos with eaf1 knockdown (Fig. 2D and E), ectopic expression
of foxo3b had no effect on the expression of either runx1 (n¼16/
23) or c-myb (n¼24/25) at 30 hpf (Fig. 4D). These data suggests
that eaf1 regulates expression of runx1 and c-myb independent of
foxo3b.
Subsequently, we examined the effect of foxo3b on lymphopoi-
esis. Contrary to that of eaf1 knockdown, ectopic expression of
foxo3b did not alter expression of rag1 and rag2 at 4.5 dpf and
6 dpf (Fig. 4E; Supplementary Fig. S11E). The development of
thymus was also not affected by ectopic expression of foxo3b as
indicated by foxn1 staining (Supplementary Fig. S11F).
To determine how eaf1 regulated runx1 and c-myb, we per-
formed promoter assays in embryos. As shown in Supplementary
Fig. S12A, ectopic expression of eaf1 enhanced runx1 promoter
luciferase activity dramatically. Similar results were obtained for c-
myb promoter assays (Supplementary Fig. S12B). However, we did
not detect any obvious repressive effects of foxo3b on runx1 and c-
myb promoter activity (data not shown); consistent with the
results obtained by WISH assays (Fig. 4D). Therefore, the effect
of eaf1 on deﬁnitive hematopoiesis might not be mediated by
foxo3b. Taken together, these results suggest that foxo3b might
serve as a key factor for mediating eaf1 function in primitive
hematopoiesis, but not in deﬁnitive hematopoiesis.
Foxo3b inhibited transcriptional activity of gata1 and spi1 through a
protein–protein interaction
We observed that eaf1 knockdown did not alter gata1 expres-
sion and in fact enhanced spi1 expression at 10s; yet, gata1 and
spi1 are key transcription factors that up-regulate erythropoiesis
and myelopoiesis, respectively; thus, we speculated that foxo3b
might inhibit gata1 and spi1 transactivation function. To test this
possibility, we constructed artiﬁcial transcription factors by clon-
ing zebraﬁsh gata1 and spi1 into the PM vector (Clontech), which
contains the GAL4 DNA binding domain (GAL4-DBD). The lucifer-
ase reporter pFR-Luc (Stratagene) harboring ﬁve-repeats of GAL4-
DBD binding site in its promoter was used to monitor the
transactivation activity of gata1 or spi1 fused with GAL4-DBD.
Luciferase assays in embryos showed that ectopic expression of
foxo3b inhibited the transactivation function of both gata1 and spi1
signiﬁcantly (Fig. 5A and B). Furthermore, using gata1 and spi1-
reporters, we showed that ectopic expression of foxo3b suppressed
the ability of Gata1 (Fig. 5C) and Spi1 (Fig. 5D) to activate
transcription, but ectopic expression of myoD (negative control)
had no effect, ruling out a non-speciﬁc suppressive effect of foxo3b
on gata1 or spi1. The expression of HA-tagged gata1, HA tagged
spi1 and HA-tagged foxo3b was conﬁrmed by Western blot
(Fig. 3K).
In addition, to determine whether there is a direct effect of eaf1
on transcriptional activity of gata1 and spi1, we co-transfected HA-
eaf1 with either PM-gata1 or PM-spi1 into HEK293T cells, and then
performed luciferase assays. However, eaf1 had no obvious effect
on enhancement of transactivation function of gata1 or spi1 (data
not shown).
Given that foxo3b can direct inhibit the transactivation function
of gata1 or spi1, we speculated that Foxo3b might interact with
Gata1 and Spi1 to act its suppressive role. To test this possibility,
we initially performed co-localization assays. Co-transfection of
GFP-tagged foxo3b and RFP-tagged gata1 into Cos-7 cells led to
their co-localization in the nucleus (Fig. 5E). Similarly, GFP-tagged
foxo3b also co-localized with RFP-tagged spi1 in the nucleus
(Fig. 5F). Subsequently, we conducted co-immunoprecipitation
assays to further evaluate the potential interaction between
Foxo3b and Gata1/Spil. HA-foxo3b vector was co-transfected with
Myc-gata1 or Myc-spi1 into HEK293T cells. As showed in Fig. 5G,
Myc-Gata1 could be co-immunoprecipitated by HA-Foxo3b using
Anti-HA agarose beads (Sigma). Similarly, Myc-Spi1 could also be
co-immunoprecipitated by HA-foxo3b (Fig. 5H). To ensure the
interaction between Foxo3b and Gata1/Spi1 was speciﬁc, we
designed a series of additional control experiments. As shown in
Supplementary Fig. S13, Foxo3b could not interact with Fli1a and
Gata2 (Supplementary Fig. S13A and B); Gata1 and Spi1 could not
interact with the transcription factor c-Myc (Supplementary Fig.
S13C and D); among 3 zebraﬁsh forkhead transcription factors,
Spi1 only interacted with Foxo3b (Supplementary Fig. S13E). Taken
together, these observations suggest that foxo3b may serve as a
mediator for eaf1 in hematopoiesis by suppressing the transcriptional
activity of gata1 and spi1 through protein–protein interaction.
Overexpression of a dominant negative form of foxo3b (dn-foxo3b)
rescued the hematopoietic deﬁciency caused by eaf1 knockdown
If foxo3b is indeed the key suppressive target of eaf1 for
mediating eaf1 function in hematopoiesis, blocking of foxo3b
function should rescue the hematopoietic deﬁciency exhibited in
eaf1 morphants. As reported previously, the N-terminus (1–304
aa) of mammalian FOXO3a is well-ﬁned dominant negative form of
FOXO3a (Charvet et al., 2003). In order to block foxo3b function
in vivo, we took advantage of its dominant negative form. We
cloned the N-terminus (1–277 aa) of zebraﬁsh foxo3b, correspond-
ing to the 1–304 aa region of mammalian Foxo3a, into the
expression vector pCGN-HAM, and vector Psp64 poly(A) (Pro-
mega) (for synthesizing mRNA). First of all, we conﬁrmed the
dominant negative form activity of the N-terminus (1–277aa) of
foxo3b. As shown in Fig. 6A and B, the ectopic expression of HA-
foxo3b and constitutively active HA-foxo3b-TM in embryos stimu-
lated FOXO reporter activity (pGL2-DBE, which harbors 6 repeats
of the daf16-binding elements), but, HA-dn-foxo3b did not do so
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(Fig. 6A). However, HA-dn-Foxo3b signiﬁcantly suppressed the
ability of HA-Foxo3b for activating the reporter (Fig. 6B). These
results indicate that the N-terminus of foxo3b could indeed act a
negative form of its full length.
If dn-foxo3b is indeed a dominant negative form of its full
length for disrupting normal function of foxo3b, it should interact
with Gata1 and Spi1 as well as its full length. To determine this, we
performed co-immunoprecipitation assays and found that dn-
Foxo3b associated with both Gata1 and Spi1 (Fig. 6C and D). We
next examined whether dn-Foxo3b could reverse the ability of
wildtype foxo3b to suppress the transactivation function of gata1
and spi1 reporters. As expected, the addition of the dn-foxo3b
vector blocked the ability of foxo3b to suppress gata1 transcrip-
tional activity (Fig. 6E). While the dn-foxo3b vector did not fully
rescue spi1 transcriptional activity, but it did diminish foxo3b-
mediated suppression statistically signiﬁcant (Fig. 6F; p¼0.0207).
Subsequently, we determined whether blocking foxo3b via its
dominant negative form would rescue eaf1 morphants. Embryos
were co-injected with Eaf1–MO3 (4 ng/per embryo) and dn-foxo3b
mRNA (820 pg/per embryo), or with GFP mRNA as a control and
then the expression of various markers was evaluated. As shown
in Fig. 6G, co-injection of dn-foxo3b as compared with GFP mRNA
Fig. 5. Foxo3b represses the transcriptional activity of Gata1 and Spi1 through protein–protein interaction. (A) Gata1 transcriptional activity was signiﬁcantly inhibited
by over-expression of foxo3b. (B) Spi1 transcriptional activity was signiﬁcantly inhibited by over-expression of foxo3b. (C) The suppression of Gata1 transcriptional activity
was conﬁrmed by gata1 reporter assays. (D) The suppression of Spi1 transcriptional activity by foxo3b was conﬁrmed by spi1 reporter assays. The dosages of injected
plasmids: gata1-reporter, spi1-reporter, 28.0 pg/per embryo; HA-empty, HA-gata1, HA-spi1, HA-foxo3b, HA-myoD, 37.5 pg/embryo; pFR, 25.0 pg/per embryo; pRL-TK, 25.0 pg/
per embryo. (E) GFP-tagged foxo3b (GFP-foxo3b) co-localized with RFP-tagged gata1 (RFP-gata1) in COS-7 cells. (F) GFP-tagged foxo3b (GFP-foxo3b) co-localized with RFP-
tagged spi1 (RFP-spi1) in COS-7 cells. (G) Foxo3b interacted with Gata1 in 293 T cells as revealed by co-immunoprecipitation assays. (H) Foxo3b interacted with Spi1 in 293 T
cells as revealed by co-immunoprecipitation assays. IB, immunoblot; IP, immunoprecipitation; TCL, total cell lysate.
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partially restored hemoglobin levels in the ventral yolk (Fig. 6G
(c)) of eaf1 morphants at 52 hpf. Consistently, expressions of
erythroid cell markers hbae3 and hbbe1 were also restored by
co-injection of dn-foxo3b mRNA at 48 hpf (Fig. 6G (d–i)) as well as
expression of myeloid markers mpo and l-plastin (Fig. 6G (j–o)).
The restoration of hbbe1, hbae3, mpo and l-plastin expression was
conﬁrmed by semi-quantitative RT-PCR (Fig. 6H, npo0.05) while
the expression of injected dn-foxo3b mRNA was conﬁrmed by
Western blot (Fig. 6I). Taken together, these results suggest that
co-injection of the dominant negative form of foxo3b could rescue
the hematopoietic deﬁciency observed in eaf1 morphants; further
reinforcing the notion that foxo3b serves as a key factor for
mediating eaf1 function in primitive hematopoiesis.
Interestingly, we also found that the suppressive role of eaf1 on
foxo3b and the inhibition role of foxo3b on spi1 and gata1
transactivation function are evolutionary conserved in mammals.
As shown in Supplementary Fig. S14, overexpression of human
EAF1 could suppress activity of human FOXO3a promoter in
HEK293T cells (Supplementary Fig. S14A (a and b)). FOXO3a could
indeed activate its reporter pGL2-DBE (Supplementary Fig. S14B
(a)). Co-transfection of FOXO3a together with GATA1 or SPI1 in
HEK293T cells suppressed activity of GATA1 reporter and SPI1
reporter signiﬁcantly (Supplementary Fig. S14B (b and c)).
Moreover, FOXO3a interacted with GATA1 or SPI1 when they were
over-expressed (Supplementary Fig. S14C (b and c)). Exploration of
the regulatory pathway EAF1-FOXO3a-GATA1/SPIi1 in mammals
may open a new window for understanding the underling
mechanisms of mammalian EAF1 and FOXO3a in hematopoiesis.
Discussion
In this study, we revealed that eaf1 is required for both
primitive hematopoiesis and deﬁnitive hematopoiesis. Moreover,
we provide evidence to show that foxo3b might serve as a key
factor for mediating eaf1 function in primitive hematopoiesis.
In addition to the defect seen in primitive hematopoiesis, eaf1
knockdown also disrupted deﬁnitive hematopoiesis, as indicated
by the reduced red blood cell number at 6.5dpf and the decreased
expression of runx1 and c-myb at 31hpf. However, ectopic expres-
sion of foxo3b did not alter expression of runx1 and c-myb,
suggesting that foxo3b does not mediate eaf1 function in deﬁnitive
hematopoiesis. Ectopic expression of eaf1, but not foxo3b, stimu-
lated both runx1 and c-myb promoter activity in embryos. Thus,
the possibility exists that eaf1 may directly up-regulate runx1 and
Fig. 6. The primitive hematopoietic deﬁciency caused by eaf1 depletion can be partially rescued by ectopic expression of the dominant negative form of foxo3b (dn-foxo3b).
(A) The dominant negative form of foxo3b (dn-foxo3b) behaved similarly to the dominant negative form of human FOXO3a (dn-FOXO3a) as predicted. Overexpression of
HA-tagged foxo3b (HA-foxo3b) as well as its active form, HA-tagged foxo3b-TM (HA-foxo3b-TM), activated the FOXO reporter (pGL2-DBE) (lanes 4 and 5) signiﬁcantly, but
overexpression of the HA-tagged dominant negative form of foxo3b (HA-dn-foxo3b) failed to do so (lane 6). The dosages of injected plasmids were pGL2-promoter, pGl2-DBE,
12.5 pg/embryo; HA-empty/foxo3b/foxo3b-TM/dn-foxo3b, 62.5pg/embryo; pRL-SV40, 25.0 pg/embryo. (B) The dominant negative form of foxo3b (dn-foxo3b) suppressed the
ability of wild type foxo3b to transactivate the foxo3b reporter (pGL2-DBE) HA-empty/foxo3b/dn-foxo3b, 37.5pg/embryo. (C) Dn-foxo3b interacted with Gata1 in 293 T cells.
(D) Dn-foxo3b interacted with Spi1 in 293 T cells. Co-immunoprecipitation assays were performed using plasmids as indicated. (E) Dn-foxo3b restored the suppressive
activity of wildtype foxo3b on gata1 reporter. (F) Dn-foxo3b could restore the suppressive activity of wildtype foxo3b on spi1 reporter. (G) O-dianisidine staining indicated that
co-injection of dn-foxo3b mRNA partially restored hemoglobin levels in eaf1 morphants (c) compared to co-injection of GFP mRNA control (b) at 52 hpf. Expression of
multiple markers hbae3 (f), hbbe1 (i), mpo (l), and l-plastin (o) could also be restored by co-injection of dn-foxo3b mRNA in eaf1 morphants, but not by co-injection of GFP
mRNA in eaf1morphants (e, h, k and n). Eaf1–MO3, 4 ng/embryo; dn-foxo3b mRNA, 820 pg/embryo. (H) Semi-quantitative RT-PCR conﬁrmed the restoration of hbbe1, hbae3,
mpo and l-plastin by co-injection of dn-foxo3b in eaf1 morphants (*po0.05). (I) The expression of injected dn-foxo3b mRNA at 52 hpf embryos was conﬁrmed by Western
blot using anti-Myc antibody.
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c-myb to affect deﬁnitive hematopoiesis, an area that requires
future study.
Given the high degree of similarity between eaf1 and eaf2 and
their partially redundant function in convergence and extension
movements (Liu et al., 2009), we examined whether some redun-
dancy existed in hematopoiesis. However, co-injection of varying
doses of eaf2 mRNA with eaf1 morpholinos did not rescue the
hematopoietic deﬁciency (data not shown), suggesting that eaf2
does not have a redundant function regarding hematopoiesis.
Notably, expression of zebraﬁsh eaf1 during early embryogenesis
is ubiquitous (Liu et al., 2009, 2013), which raised a weakness for
explaining speciﬁc hematopoietic defects observed in eaf1 mor-
phants. Given the complex pathways that regulate hematopoiesis,
eaf1, perhaps similar to other individual factors, might only have
partial effects on the process (Choorapoikayil et al., 2013;
Hirabayashi et al., 2013; Li et al., 2012; Tsao et al., 2013).
In addition, further microarray analysis identiﬁed foxo3b as a
major target of eaf1 and the subsequent biochemical evaluation
revealed that Foxo3b speciﬁcally interact with Gata1 and Spi1 to
inhibit their transactivation function. Gata1 and Spi1 have been
suggested to regulate erythropoiesis and myelopoiesis in a cell
autonomous manner (Pevny et al., 1991; Scott et al., 1997; Vyas
et al., 1999), implying cell autonomy given the hematopoietic-
restricted gene expression pattern.
While studies have shown positive auto-regulatory activity of
gata1 and spi1 during hematopoiesis (Chen et al., 1995; Tsai et al.,
1991), we did not detect a decrease in expression of either gene in
the microarray analysis, suggesting that some targets may have
been missed. In fact, co-injection of dn-foxo3b did not completely
restore hemoglobin and mpo levels to that of the wildtype control,
implying that other unidentiﬁed eaf1 downstream factors may also
contribute to eaf1 function in hematopoiesis.
As a tumor suppressor, the role of mammalian FOXO3a in
hematopoiesis has generated much interest. It has been reported
that FOXO3a regulates erythroid differentiation by inducing BTG1
(Bakker, 2004). In addition, FOXO3a is essential for maintaining the
hematopoietic stem cell pool and the self-renewal capacity of
HSCs (Miyamoto et al., 2007; Tothova et al., 2007). Sykes et al.
reported that either activation of Akt or compound deletion of
FOXO1/3/4 reduced leukemic cell growth, suggesting that FOXO
gene depletion can also reduce blood cell number (Sykes et al.,
2011). Here, we showed that up-regulation of foxo3b resulting
from eaf1 depletion caused blood cell number reduction. It
appears that dys-regulation of foxo3b, either by stimulation or by
knockdown/out, might disrupt the normal program of hematopoi-
esis. Therefore, the maintenance of appropriate levels of foxo3b
during embryogenesis might be essential for blood cell growth
and differentiation.
An interesting phenomenon in this study was that expression
of spi1 in eaf1 morphants: spi1 mRNA increased at 10s (Fig. 1E),
but then decreased at 22 hpf (Fig. 1F and G). Ectopic expression
of foxo3b in embryos also inhibited spi1 expression at 10s
(Supplementary Fig. S11D). Moreover, both eaf1 and foxo3b sup-
pressed spi1 promoter activity dramatically (Supplementary Fig.
S15), indicating both eaf1 and foxo3b have a suppressive role on
spi1 expression. Thus, it appears that during the early stage of eaf1
morphants, the depletion of eaf1 led to increased both spi1 and
foxo3b, but the dramatic increase of foxo3b eventually repressed
spi1 expression, resulting in spi1 expression reduced at later stage
(22 hpf). Taken together, foxo3b might regulate myelopoiesis in
two ways: by inhibiting spi1 transactivation function through
protein–protein interaction, and by directly suppressing spi1
expression at later stages of embryogenesis.
In summary, our study reveal an essential role of eaf1 in
hematopoiesis and identify foxo3b as a suppressive target of eaf1
to mediate eaf1 function in primitive hematopoiesis. To better
understand the physiological relevance of the regulatory pathway,
eaf1–foxo3b–gata1/spi1, may shed light on the illustration of
molecular mechanism of MLL–ELL related leukemogenesis, leading
to the development of new treatments for MLL–ELL induced acute
myeloid leukemia.
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